Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
复制标题
DOI：
10.1038/s41591-022-01701-w
复制
发表时间：
2022-04
期刊：
影响因子：
82.9
通讯作者：
Boaventura, Viviane S.
中科院分区：
文献类型：
--
作者：
Cerqueira-Silva, Thiago;Katikireddi, Srinivasa Vittal;Oliveira, Vinicius de Araujo;Flores-Ortiz, Renzo;Bertoldo Junior, Juracy;Paixao, Enny S.;Robertson, Chris;Penna, Gerson O.;Werneck, Guilherme L.;Barreto, Mauritio L.;Pearce, Neil;Sheikh, Aziz;Barral-Netto, Manoel;Boaventura, Viviane S.
人们对2019年冠状病毒病(新冠肺炎)疫苗效力的减弱和加强剂量的疫苗效力(VE)相当感兴趣。使用链接的巴西国家数据库，我们进行了一项涉及近1,400万人(约1,600万项测试)的试验阴性设计研究，以估计随着时间的推移冠状病毒的VE和BNT162b2加强疫苗接种RT-PCR确认的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染和严重新冠肺炎结局(住院或死亡)的VE。与未接种的个体相比，第二次接种后14-30d的冠状病毒VE对确认感染和严重后果的预测值分别为55.0%(95%可信区间：54.3-55.7)和82.1%(95%CI：81.4-82.8)。第二次服药后180d，VE下降到34.7%(95%CI：33.1~36.2)，VE下降到72.5%(95%CI：70.9~74.0)。BNT162b2强化免疫后6个月，VE对感染的抵抗率为92.7%(95%CI：91.0−94.0)，VE对严重后果的抵抗率为97.3%(95%CI：96.1−98.1)。与年轻年龄组相比，80岁或以上的人在第二次接种后的保护较低，但在加强免疫后的保护相似。我们的发现支持在两剂CoronaVac后接种BNT162b2加强疫苗，特别是对老年人。对来自巴西的数据进行的一项试验阴性病例对照分析表明，接种两剂冠状病毒后，针对SARS-CoV-2感染和严重新冠肺炎结局的疫苗效力下降，但在加强剂量BNT162b2疫苗后增加。
There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly. A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.
登录
查看更多内容
影响因子：
7.8
作者：
Bichara CDA;Queiroz MAF;da Silva Graça Amoras E;Vaz GL;Vallinoto IMVC;Bichara CNC;Amaral IPCD;Ishak R;Vallinoto ACR
通讯作者：
Vallinoto ACR
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
DOI：
10.1198/016214504000000980
发表时间：
2004-09-01
影响因子：
3.7
作者：
Wood, SN
通讯作者：
Wood, SN
DOI：
10.1016/j.lana.2021.100154
发表时间：
2022-03
期刊：
Lancet regional health. Americas
影响因子：
--
作者：
Cerqueira-Silva T;Oliveira VA;Boaventura VS;Pescarini JM;Júnior JB;Machado TM;Flores-Ortiz R;Penna GO;Ichihara MY;de Barros JV;Barreto ML;Werneck GL;Barral-Netto M
通讯作者：
Barral-Netto M
DOI：
10.1016/s2666-5247(21)00129-4
发表时间：
2021-10
期刊：
The Lancet. Microbe
影响因子：
--
作者：
Souza WM;Amorim MR;Sesti-Costa R;Coimbra LD;Brunetti NS;Toledo-Teixeira DA;de Souza GF;Muraro SP;Parise PL;Barbosa PP;Bispo-Dos-Santos K;Mofatto LS;Simeoni CL;Claro IM;Duarte ASS;Coletti TM;Zangirolami AB;Costa-Lima C;Gomes ABSP;Buscaratti LI;Sales FC;Costa VA;Franco LAM;Candido DS;Pybus OG;de Jesus JG;Silva CAM;Ramundo MS;Ferreira GM;Pinho MC;Souza LM;Rocha EC;Andrade PS;Crispim MAE;Maktura GC;Manuli ER;Santos MNN;Camilo CC;Angerami RN;Moretti ML;Spilki FR;Arns CW;Addas-Carvalho M;Benites BD;Vinolo MAR;Mori MAS;Gaburo N;Dye C;Marques-Souza H;Marques RE;Farias AS;Diamond MS;Faria NR;Sabino EC;Granja F;Proença-Módena JL
通讯作者：
Proença-Módena JL